Losmapimod for use in treating glomerular disease
View Patent ↗The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
1. A method for treating focal segmental glomerulosclerosis (FSGS) in a subject in need thereof comprising administering to said subject a pharmaceutical formulation comprising the compound 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the pharmaceutical formulation is adapted for oral administration.
3. The method of claim 1 , wherein the pharmaceutical formulation comprises one or more other therapeutic agents which are suitable for the treatment of focal segmental glomerulosclerosis (FSGS).
4. The method of claim 1 , wherein the compound 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl)-nicotinamide is in the form of a free base.
5. The method of claim 4 , wherein the pharmaceutical formulation is adapted for oral administration.
6. The method of claim 4 , wherein the pharmaceutical formulation further comprises one or more other therapeutic agents which are suitable for the treatment of focal segmental glomerulosclerosis (FSGS).